Former Biogen R&D Chief Surfaces With Exosome-Focused Startup
This article was originally published in Scrip
Executive Summary
Douglas Williams turned heads in July when Biogen revealed that its executive vice president leading research and development was leaving to found a biotechnology startup, and now Williams has emerged from the fundraising process as the president and CEO of Codiak BioSciences with venture capital to develop exosomes-based therapeutics and diagnostics.
You may also be interested in...
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.